One study conducted in 2011 in 10 patients revealed the development of demyelination events as a result of TNF-α inhibitor therapy with a clear distinction from sporadic multiple sclerosis; most symptoms occurred within one year from the beginning of the therapy [151]. Here, TNF is linked to multiple sclerosis.